Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1162 participants.

Also called NCT01368081

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,162 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01368081
Other papers using this trial's data
  • Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus Diabetes, obesity & metabolism, 2015-07 DOI, PubMed 25772548

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01368081. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-06-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Metformin
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo (low dose)
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo (high dose)
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01368081
Content hash
da97cb7f7b1c3a2e9c4acae88720fa7437ed48fb390a518e022e990d2eecfaa2